SITC 2021 | Adjuvant nivolumab in patents with high-risk resected melanoma
Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York City, NY, discusses the results from a study making an indirect treatment comparison of adjuvant nivolumab versus placebo in patents with high-risk resected melanoma. This analysis used data from the phase III CheckMate 238 (NCT02388906) trial comparing nivolumab and ipilimumab and from the EORTC 18071 trial (NCT00636168) comparing ipilimumab vs placebo. Results showed that nivolumab was associated with clinically meaningful improvements in recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in comparison to placebo in this patient population. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Disclosures
I consult for and have received less than $10,000 dollars per annum from Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Celldex, Incyte, Biond, ImCheck, Sellas, Evaxion and EMD Serono and $10-25,000 dollars from BMS for membership on Advisory Boards
I hold equity in Biond, Evaxion, Instil Bio, OncoC4 and Neximmune
I am on scientific advisory boards for Evaxion, ImCheck, Biond, Sellas, Instil Bio, OncoC4 and Neximmune and am remunerated between $10,000-$75,000 dollars
I am not a member of any speaker’s bureau
NYU, but not me personally, received research support from BMS, Merck, GSK, Moderna, Pfizer, Novartis and Astra Zeneca
Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on; I receive less than $1500 yearly in royalties
